Observed and Modeled Positive Predictive Values Using Cell-free DNA Testing for Fetal Trisomy in a Clinical Laboratory Population

Fetal Diagn Ther. 2021;48(2):134-139. doi: 10.1159/000512501. Epub 2021 Jan 20.

Abstract

Introduction: The objective of this study was to explore different approaches to communicating the positive predictive value (PPV) of cell-free DNA screening for fetal trisomy.

Methods: PPV was established for 4 maternal age-groups (<30, 30-34, 35-39, and >39 years) from clinical laboratory data and compared to the modeled PPV from an online calculator. In women under 35, PPV was compared between 2 subsets, high risk and low risk, classified based on the diagnosis codes that were provided to the laboratory.

Results: In 503 high-probability trisomy 21 results, the observed PPVs in the 4 age-groups were 97.0% (<30), 98.9% (30-34), 99.5% (35-39), and 96.3% (>39), all higher than those from the calculator, which ranged from 53 to 95%. Likewise, PPVs were 77.4-97.0% observed versus 16-78% modeled in 131 trisomy 18 cases and 30.4-80.0% observed versus 6-61% modeled in 80 trisomy 13 cases. In women under 35, PPV for the trisomies combined was 90.4% in the higher-risk group compared to 79.7% in the lower-risk group.

Conclusion: Modeling PPV based on maternal age will provide an underestimate in a clinical population. Although the PPV is higher for the samples with higher-risk diagnosis codes, the information that accompanies clinical samples is too general to model PPV for a specific patient.

Keywords: Cell-free DNA testing; Noninvasive prenatal testing; Positive predictive value; Prenatal screening.

MeSH terms

  • Adult
  • Cell-Free Nucleic Acids*
  • Chromosome Disorders* / diagnosis
  • Chromosome Disorders* / genetics
  • Chromosomes, Human, Pair 18
  • Female
  • Humans
  • Laboratories
  • Predictive Value of Tests
  • Pregnancy
  • Prenatal Diagnosis
  • Trisomy / diagnosis
  • Trisomy / genetics
  • Trisomy 13 Syndrome / diagnosis

Substances

  • Cell-Free Nucleic Acids